| Literature DB >> 31412929 |
Hong Ki Min1, Jennifer Lee2, Ji Hyeon Ju2, Sung-Hwan Park2, Seung-Ki Kwok3.
Abstract
BACKGROUND: The purpose of the present study was to demonstrate whether alcohol consumption could predict spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort study.Entities:
Keywords: Alcohol; Axial spondyloarthritis; Syndesmophyte; mSASSS
Mesh:
Year: 2019 PMID: 31412929 PMCID: PMC6692958 DOI: 10.1186/s13075-019-1970-3
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Fig. 1Flow chart showing participation from enrollment to the 2-year follow-up and reasons for exclusion from analysis. axSpA, axial spondyloarthritis; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score
Comparison of characteristics between alcohol drinker and non-drinker
| Total axSpA ( | Non-drinker ( | Alcohol drinker ( |
| |
|---|---|---|---|---|
| Age (years) | 39.0 ± 11.1 | 39.8 ± 13.4 | 38.7 ± 10.3 | 0.516 |
| Diagnosed age (years) | 31.4 ± 11.5 | 32.9 ± 13.3 | 30.8 ± 10.7 | 0.227 |
| Disease duration (years) | 7.5 ± 6.2 | 6.8 ± 5.8 | 7.7 ± 6.3 | 0.292 |
| Follow-up duration (months) | 24.03 ± 1.55 | 24.11 ± 1.59 | 24.01 ± 1.54 | 0.601 |
| Male (%) | 214 (77.0%) | 48 (66.7%) | 166 (80.6%) | 0.024 |
| BMI (kg/m2) | 24.0 ± 3.2 | 23.9 ± 3.5 | 24.0 ± 3.1 | 0.856 |
| Obesity (BMI ≥ 25 kg/m2) | 95 (34.2%) | 23 (31.9%) | 72 (35.0%) | 0.750 |
| BMI ≥ 30 kg/m2 | 9 (3.2%) | 2 (2.8%) | 7 (3.4%) | 1.000 |
| Current smoker (%) | 75 (27.1%) | 11 (15.3%) | 64 (31.2%) | 0.014 |
| Alcohol consumption (unit/week) | 12.6 ± 15.0 | |||
| Uveitis history (%) | 125 (45.5%) | 42 (59.2%) | 83 (40.7%) | 0.011 |
| IBD history (%) | 3 (1.1%) | 1 (1.4%) | 2 (1.0%) | 1.000 |
| Dactylitis history (%) | 21 (7.6%) | 6 (8.5%) | 15 (7.4%) | 0.968 |
| Psoriasis history (%) | 15 (5.5%) | 3 (4.2%) | 12 (5.9%) | 0.821 |
| BASDAI (0–10) | 2.9 ± 1.9 | 3.1 ± 1.9 | 2.9 ± 1.9 | 0.281 |
| ASDAS-ESR (0–10) | 1.9 ± 0.9 | 2.0 ± 0.9 | 1.9 ± 0.9 | 0.274 |
| ASDAS-CRP (0–10) | 1.8 ± 0.8 | 1.8 ± 0.8 | 1.8 ± 0.9 | 0.668 |
| BASFI (0–10) | 0.8 ± 1.2 | 1.0 ± 1.4 | 0.8 ± 1.2 | 0.400 |
| PGA (0–10) | 3.1 ± 2.2 | 3.3 ± 2.5 | 3.1 ± 2.1 | 0.570 |
| Pain VAS (0–10) | 2.8 ± 2.4 | 3.3 ± 2.5 | 2.7 ± 2.3 | 0.092 |
| PhyGA (0–10) | 2.4 ± 1.7 | 2.5 ± 1.9 | 2.3 ± 1.6 | 0.352 |
| Peripheral arthritis (%) | 21 (7.7%) | 6 (8.7%) | 15 (7.4%) | 0.928 |
| SPARCC Enthesitis index (0–16) | 0.2 ± 0.7 | 0.2 ± 0.7 | 0.2 ± 0.8 | 0.569 |
| EQ-5D-5L-TTO | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.074 |
| EQ-VAS (0–100) | 72.8 ± 17.6 | 71.7 ± 17.9 | 73.3 ± 17.5 | 0.510 |
| ASAS health index (HI, 0–17) | 3.3 ± 3.0 | 4.1 ± 3.6 | 3.0 ± 2.8 | 0.019 |
| Environmental factor related to ASAS HI (0–9) | 2.0 ± 1.5 | 2.3 ± 1.6 | 1.9 ± 1.4 | 0.058 |
| Positive HLA-B27 (%) | 248 (93.9%) | 65 (95.6%) | 183 (93.4%) | 0.714 |
| AS (satisfying mNY criteria, %) | 199 (71.6%) | 50 (69.4%) | 149 (72.3%) | 0.752 |
| Mean grade of sacroiliitis | 2.4 ± 1.1 | 2.3 ± 1.0 | 2.5 ± 1.1 | 0.217 |
| Baseline mSASSS (0–72) | 11.6 ± 16.1 | 11.2 ± 15.3 | 11.7 ± 16.4 | 0.796 |
| Baseline syndemophyte count (0–24) | 4.0 ± 5.7 | 3.8 ± 5.3 | 4.1 ± 5.9 | 0.717 |
| mSASSS change for 2 years | 2.4 ± 3.4 | 1.5 ± 2.8 | 2.7 ± 3.6 | 0.007 |
| Syndemophyte change for 2 years | 0.7 ± 1.3 | 0.4 ± 1.2 | 0.9 ± 1.3 | 0.003 |
| Current medication | ||||
| NSAID (%) | 197 (70.9%) | 53 (73.6%) | 144 (69.9%) | 0.656 |
| ASAS NSAID index (0–100) | 39.5 ± 36.1 | 40.9 ± 36.8 | 39.0 ± 35.9 | 0.702 |
| TNF-α inhibitor (%) | 146 (52.5%) | 40 (55.6%) | 106 (51.5%) | 0.644 |
| Sulfasalazine (%) | 85 (30.6%) | 17 (23.6%) | 68 (33.0%) | 0.180 |
| Methotrexate (%) | 6 (2.2%) | 2 (2.8%) | 4 (1.9%) | 1.000 |
| Bisphosphonate (%) | 23 (8.3%) | 7 (9.7%) | 16 (7.8%) | 0.787 |
| Vitamin D (%) | 88 (31.7%) | 26 (36.1%) | 62 (30.1%) | 0.425 |
Continuous variables are presented as mean ± standard deviation
ASAS Assessment of SpondyloArthritis international Society, ASDAS Ankylosing Spondylitis Disease Activity Score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BMI body mass index, CRP C-reactive protein, EQ-5D EuroQol-5 dimensions, ESR erythrocyte sedimentation rate, HLA human leukocyte antigen, IBD inflammatory bowel disease, mNY modified New York, mSASSS modified Stoke Ankylosing Spondylitis Spinal Score, NSAID nonsteroidal anti-inflammatory drug, PGA patient’s global assessment, PhyGA physician’s global assessment, SPARCC Spondyloarthritis Research Consortium of Canada, TNF tumor necrosis factor, TTO time trade-off, VAS visual analog scale
Fig. 2Proportion of radiographic spinal progression defined as mSASSS worsening more than 2 units over 2 years (a) and new syndesmophytes/progression of pre-existing syndesmophytes over 2 years (b) in alcohol drinking (n = 206) and non-drinking (n = 72) axSpA patients
Fig. 3Cumulative probability plot of 2-year progression in the modified Stoke Ankylosing Spine Score (mSASSS) according to non-drinkers (orange circles) and alcohol drinkers (blue circles) over individual intervals
Univariable and multivariable regression analyses of predicting worsening 2 units or more of mSASSS over 2 years
| Univariable | Model 1* | Model 2† | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| |
| Age | 1.039 | 1.016, 1.062 | 0.001 | 1.025 | 0.997, 1.054 | 0.077 | 1.027 | 0.999, 1.056 | 0.061 |
| Male | 1.580 | 0.900, 2.774 | 0.111 | 1.477 | 0.768, 2.840 | 0.243 | |||
| Obesity (BMI ≥ 25 kg/m2) | 1.074 | 0.653, 1.764 | 0.779 | ||||||
| Alcohol drinker | 3.748 | 2.098, 6.694 | < 0.001 | 4.748 | 2.488, 9.061 | < 0.001 | 4.401 | 2.287, 8.469 | < 0.001 |
| Current smoker | 1.317 | 0.772, 2.248 | 0.312 | 1.039 | 0.567, 1.905 | 0.900 | |||
| Uveitis history | 1.870 | 1.155, 3.029 | 0.011 | 2.117 | 1.214, 3.689 | 0.008 | 2.119 | 1.212, 3.704 | 0.008 |
| Elevated BASDAI (≥ 4) | 1.218 | 0.713, 2.081 | 0.471 | ||||||
| Very high ASDAS-CRP (> 3.5) | 3.232 | 0.870, 12.015 | 0.080 | 3.049 | 0.760, 12.234 | 0.116 | 3.391 | 0.825, 13.938 | 0.090 |
| Positive HLA-B27 | 0.843 | 0.304, 2.335 | 0.743 | ||||||
| Mean grade of sacroiliitis | 1.554 | 1.230, 1.963 | < 0.001 | ||||||
| Pre-existing syndesmophyte | 2.268 | 1.380, 3.729 | < 0.001 | 1.762 | 0.956, 3.247 | 0.069 | 1.644 | 0.882, 3.065 | 0.117 |
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, CI confidence interval, CRP C-reactive protein, OR odd ratio
*All variables yielding a P value under 0.1 in univariable logistic regression analysis were included in model 1, except variables showing multicolinearity with other variables
†Multivariable logistic regression analysis was performed by adding gender and smoking status to the variables included in model 1
Univariable and multivariable regression analyses of predicting new syndesmophyte or pre-existing syndesmophyte progression over 2 years
| Univariable | Model 1* | Model 2† | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| |
| Age | 1.036 | 1.013, 1.059 | 0.002 | 1.026 | 0.998, 1.055 | 0.073 | 1.026 | 0.997, 1.055 | 0.076 |
| Male | 2.119 | 1.172, 3.833 | 0.013 | 2.271 | 1.163, 4.435 | 0.016 | 2.521 | 1.262, 5.036 | 0.009 |
| Obesity (BMI ≥ 25 kg/m2) | 0.955 | 0.580, 1.572 | 0.955 | ||||||
| Alcohol drinker | 2.957 | 1.637, 5.340 | < 0.001 | 3.219 | 1.671, 6.201 | < 0.001 | 3.239 | 1.673, 6.271 | < 0.001 |
| Current smoker | 1.032 | 0.606, 1.758 | 0.908 | 0.776 | 0.424, 1.418 | 0.409 | |||
| Uveitis history | 2.061 | 1.270, 3.343 | 0.003 | 2.368 | 1.364, 4.113 | 0.002 | 2.295 | 1.319, 3.994 | 0.003 |
| Elevated BASDAI (≥ 4) | 1.104 | 0.646, 1.887 | 0.717 | ||||||
| Very high ASDAS-CRP (> 3.5) | 4.474 | 1.203, 16.640 | 0.025 | 5.638 | 1.361, 23.357 | 0.017 | 5.536 | 1.325, 23.136 | 0.019 |
| Positive HLA-B27 | 0.610 | 0.220, 1.690 | 0.342 | ||||||
| Mean grade of sacroiliitis | 1.497 | 1.184, 1.892 | 0.001 | ||||||
| Pre-existing syndesmophyte | 2.057 | 1.243, 3.406 | 0.005 | 1.400 | 0.746, 2627 | 0.295 | 1.410 | 0.747, 2.662 | 0.289 |
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, CI confidence interval, CRP C-reactive protein, OR odd ratio
*All variables yielding a P value under 0.1 in univariable logistic regression analysis were included in model 1, except variables showing multicolinearity with other variables
†Multivariable logistic regression analysis was performed by adding smoking status to the variables included in model 1